Tharimmune Inc., a clinical-stage biotechnology and digital asset company, has announced the appointment of Jacob Asbury as chief financial officer, effective immediately. The move, disclosed on December 12, 2025, aligns with Tharimmune’s innovative digital asset treasury strategy centered on Canton Coin, aiming to drive financial operations and shareholder value. Asbury’s experience is expected to bolster the company’s financial planning and treasury management amid expanding initiatives.

Tharimmune Advances Financial Leadership With CFO Appointment

Jacob Asbury’s appointment as CFO arrives as Tharimmune expands its dual focus on biotech research and digital asset investments. Asbury previously held CFO roles at Clear Street Group Inc., Performance Flight & Custom Jet Charters, and Instinet Incorporated. He also led an independent advisory practice specializing in financial systems implementation and process automation. Asbury holds a bachelor’s degree from the University of Vermont.

Mark Wendland, CEO of Tharimmune, praised Asbury’s “deep financial leadership experience and a track record of delivering innovative approaches to financial operations,” emphasizing the importance of this expertise for creating shareholder value through the company’s digital asset treasury strategy.

Driving the Canton Coin Digital Asset Strategy

Since November 2025, Tharimmune has pursued an ambitious digital asset treasury strategy involving Canton Coin. The company describes itself as the first publicly traded firm to leverage Canton Coin in support of the Canton Network’s goal to digitize traditional financial markets. Initiatives include acquiring Canton Coin, applying to operate as a Super Validator, and investing in applications built on the Canton Network.

This strategy reflects Tharimmune’s unique position bridging biotechnology and blockchain-enabled financial products. With these intersecting sectors, Asbury’s role will be critical in ensuring operational excellence, accurate financial reporting, and efficient capital deployment.

Appointment: Market Outlook

The appointment of Jacob Asbury as chief financial officer represents a strategic enhancement of Tharimmune’s financial leadership amid its cutting-edge digital asset endeavors. His diverse CFO experience supports the company’s goals to optimize capital planning and treasury management through 2026. Investors should monitor how Asbury’s leadership impacts the execution of Tharimmune’s Canton Coin treasury program and its biotech research activities.